Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (44)	12/1/2001 12:29:01 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 118

Hi Vector, I have re-entered KOSP after being out for quite a while. (The ramp of Niaspan has been modest. I considered the selection of DuPont as a weak deal.) I have read, The Heart Disease Breakthrough by Yannios and buy the role of niacin in management of CHD. The NEJM article will help get the attention of doctors for a much needed shift in treatment. The success of KOSP requires a powerful marketing effort. So for me, we have a coming litmus test. Is the marketing partner powerful and motivated? When the marketing partner is announced we will all get a chance to assess the deal and KOSP's future. I certainly will be doing that. ij PS - Glad to see this thread come alive - it is timely. While the Yahoo thread is fine for now - Yahoo is too prone to nuts taking over. Thanks for the awakening.